CAT

895.69

-3.29%↓

302.72

-1.09%↓

GEV.US

1,045.23

-6.67%↓

RTX

176.79

-0.03%↓

231.1

+0.53%↑

CAT

895.69

-3.29%↓

302.72

-1.09%↓

GEV.US

1,045.23

-6.67%↓

RTX

176.79

-0.03%↓

231.1

+0.53%↑

CAT

895.69

-3.29%↓

302.72

-1.09%↓

GEV.US

1,045.23

-6.67%↓

RTX

176.79

-0.03%↓

231.1

+0.53%↑

CAT

895.69

-3.29%↓

302.72

-1.09%↓

GEV.US

1,045.23

-6.67%↓

RTX

176.79

-0.03%↓

231.1

+0.53%↑

CAT

895.69

-3.29%↓

302.72

-1.09%↓

GEV.US

1,045.23

-6.67%↓

RTX

176.79

-0.03%↓

231.1

+0.53%↑

Home・Akciju saraksts・CryoPort Inc

CryoPort Inc

Slēgts

SektorsRūpniecība

12.69 0.55

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.55

Max

13.25

Galvenie mērījumi
By Trading Economics
Ienākumi	-17M -24M
Pārdošana	2.3M 48M
Peļņas marža	-51.98
Darbinieki	684
EBITDA	-5.9M -9.6M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+7.01% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.5M 513M
Iepriekšējā atvēršanas cena	12.14
Iepriekšējā slēgšanas cena	12.69

Ziņu noskaņojums

By Acuity

50%

215 / 405 Rangs Industrials

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

5.615 / N/A Atbalsts un pretestība

CryoPort Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. maijs 23:58 UTC

Peļņas

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026. g. 7. maijs 22:57 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026. g. 7. maijs 23:52 UTC

Peļņas

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026. g. 7. maijs 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 7. maijs 23:39 UTC

Tirgus saruna

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026. g. 7. maijs 23:28 UTC

Tirgus saruna

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026. g. 7. maijs 23:11 UTC

Peļņas

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026. g. 7. maijs 23:06 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026. g. 7. maijs 23:05 UTC

Peļņas

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026. g. 7. maijs 23:04 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026. g. 7. maijs 23:02 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026. g. 7. maijs 23:00 UTC

Tirgus saruna

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026. g. 7. maijs 22:42 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026. g. 7. maijs 22:33 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026. g. 7. maijs 22:32 UTC

Peļņas

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie: 68% of FY Income From International >MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026. g. 7. maijs 22:29 UTC

Peļņas

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026. g. 7. maijs 22:26 UTC

Peļņas

Macquarie to End Share Buyback Extended in November>MQG.AU

2026. g. 7. maijs 22:25 UTC

Peļņas

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Salīdzinājums

Cenas izmaiņa

CryoPort Inc Prognoze

Cenas mērķis

By TipRanks

7.01% augšup

Prognoze 12 mēnešiem

Vidējais 13.58 USD 7.01%

Augstākais 17 USD

Zemākais 9.5 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CryoPort Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CryoPort Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

5.615 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

There is one bullish event.

Noskaņojums

By Acuity

215 / 405 Rangs Rūpniecība

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CryoPort Inc

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.